vs

Side-by-side financial comparison of Investar Holding Corp (ISTR) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Investar Holding Corp is the larger business by last-quarter revenue ($23.5M vs $12.5M, roughly 1.9× Avidity Biosciences, Inc.). On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 0.9%). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 4.9%).

Investar Holding Corp is a U.S.-headquartered bank holding company that primarily operates across the Gulf Coast region. It delivers a full range of commercial and retail banking services, including deposit products, consumer and business loans, mortgage services, and wealth management solutions for individual clients, small and medium-sized enterprises, and commercial entities.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

ISTR vs RNA — Head-to-Head

Bigger by revenue
ISTR
ISTR
1.9× larger
ISTR
$23.5M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+433.2% gap
RNA
434.0%
0.9%
ISTR
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
4.9%
ISTR

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ISTR
ISTR
RNA
RNA
Revenue
$23.5M
$12.5M
Net Profit
$-174.4M
Gross Margin
Operating Margin
30.9%
-1513.5%
Net Margin
-1398.3%
Revenue YoY
0.9%
434.0%
Net Profit YoY
-117.0%
EPS (diluted)
$0.50
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ISTR
ISTR
RNA
RNA
Q4 25
$23.5M
Q3 25
$24.1M
$12.5M
Q2 25
$22.3M
$3.8M
Q1 25
$24.0M
$1.6M
Q4 24
$23.3M
$3.0M
Q3 24
$22.3M
$2.3M
Q2 24
$20.4M
$2.0M
Q1 24
$21.4M
$3.5M
Net Profit
ISTR
ISTR
RNA
RNA
Q4 25
Q3 25
$6.2M
$-174.4M
Q2 25
$4.5M
$-157.3M
Q1 25
$6.3M
$-115.8M
Q4 24
$-102.3M
Q3 24
$5.4M
$-80.4M
Q2 24
$4.1M
$-70.8M
Q1 24
$4.7M
$-68.9M
Operating Margin
ISTR
ISTR
RNA
RNA
Q4 25
30.9%
Q3 25
31.0%
-1513.5%
Q2 25
24.4%
-4448.7%
Q1 25
32.2%
-8360.9%
Q4 24
31.1%
-4069.6%
Q3 24
27.6%
-4200.9%
Q2 24
24.0%
-4040.4%
Q1 24
28.5%
-2178.6%
Net Margin
ISTR
ISTR
RNA
RNA
Q4 25
Q3 25
25.6%
-1398.3%
Q2 25
20.2%
-4089.3%
Q1 25
26.3%
-7360.0%
Q4 24
-3439.5%
Q3 24
24.1%
-3441.7%
Q2 24
19.9%
-3461.8%
Q1 24
22.0%
-1943.4%
EPS (diluted)
ISTR
ISTR
RNA
RNA
Q4 25
$0.50
Q3 25
$0.54
$-1.27
Q2 25
$0.46
$-1.21
Q1 25
$0.63
$-0.90
Q4 24
$0.61
$-0.80
Q3 24
$0.54
$-0.65
Q2 24
$0.41
$-0.65
Q1 24
$0.48
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ISTR
ISTR
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$350.2M
Total DebtLower is stronger
$9.8M
Stockholders' EquityBook value
$301.1M
$1.9B
Total Assets
$2.8B
$2.1B
Debt / EquityLower = less leverage
0.03×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ISTR
ISTR
RNA
RNA
Q4 25
Q3 25
$350.2M
Q2 25
$243.9M
Q1 25
$254.2M
Q4 24
$219.9M
Q3 24
$370.2M
Q2 24
$575.8M
Q1 24
$471.4M
Total Debt
ISTR
ISTR
RNA
RNA
Q4 25
$9.8M
Q3 25
Q2 25
Q1 25
Q4 24
$9.8M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ISTR
ISTR
RNA
RNA
Q4 25
$301.1M
Q3 25
$295.3M
$1.9B
Q2 25
$255.9M
$1.2B
Q1 25
$251.7M
$1.3B
Q4 24
$241.3M
$1.4B
Q3 24
$245.5M
$1.5B
Q2 24
$230.2M
$1.2B
Q1 24
$227.0M
$830.9M
Total Assets
ISTR
ISTR
RNA
RNA
Q4 25
$2.8B
Q3 25
$2.8B
$2.1B
Q2 25
$2.7B
$1.4B
Q1 25
$2.7B
$1.5B
Q4 24
$2.7B
$1.6B
Q3 24
$2.8B
$1.6B
Q2 24
$2.8B
$1.3B
Q1 24
$2.8B
$951.5M
Debt / Equity
ISTR
ISTR
RNA
RNA
Q4 25
0.03×
Q3 25
Q2 25
Q1 25
Q4 24
0.04×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ISTR
ISTR
RNA
RNA
Operating Cash FlowLast quarter
$18.2M
$-156.2M
Free Cash FlowOCF − Capex
$-156.9M
FCF MarginFCF / Revenue
-1257.6%
Capex IntensityCapex / Revenue
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ISTR
ISTR
RNA
RNA
Q4 25
$18.2M
Q3 25
$6.9M
$-156.2M
Q2 25
$3.2M
$-199.7M
Q1 25
$4.5M
$-124.8M
Q4 24
$15.9M
$-99.9M
Q3 24
$5.6M
$-65.6M
Q2 24
$2.8M
$-65.0M
Q1 24
$7.8M
$-70.4M
Free Cash Flow
ISTR
ISTR
RNA
RNA
Q4 25
Q3 25
$-156.9M
Q2 25
$-203.0M
Q1 25
$-128.6M
Q4 24
$-103.8M
Q3 24
$-67.3M
Q2 24
$-65.5M
Q1 24
$-71.3M
FCF Margin
ISTR
ISTR
RNA
RNA
Q4 25
Q3 25
-1257.6%
Q2 25
-5277.1%
Q1 25
-8174.3%
Q4 24
-3491.0%
Q3 24
-2881.8%
Q2 24
-3204.6%
Q1 24
-2012.3%
Capex Intensity
ISTR
ISTR
RNA
RNA
Q4 25
Q3 25
5.7%
Q2 25
86.9%
Q1 25
238.6%
Q4 24
131.7%
Q3 24
72.9%
Q2 24
26.0%
Q1 24
25.8%
Cash Conversion
ISTR
ISTR
RNA
RNA
Q4 25
Q3 25
1.12×
Q2 25
0.71×
Q1 25
0.71×
Q4 24
Q3 24
1.03×
Q2 24
0.70×
Q1 24
1.66×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons